[1]
|
Sioka C,Fotopoulos A,Kyritsis A P. Recent advances in PET imaging forevaluation of Parkinson's disease[J]. Eur J Nucl Med Mol Imaging,2010,37(8):1594-1603. doi: 10.1007/s00259-009-1357-9
|
[2]
|
Wei X,Ma T,Cheng Y,et al. Dopamine D1 or D2 receptor-expressing neurons in the central nervous system[J]. Addict Biol,2018,23(2):569-584. doi: 10.1111/adb.12512
|
[3]
|
Zang X,Cheng Z Y,Sun Y,et al. The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ1-42-induced cognitive impairment[J]. Prog Neuropsychopharmacol Biol Psychiatry,2018,2(81):250-261.
|
[4]
|
Kim M,Custodio R J,Lee H J,et al. Per2 Expression regulates the spatial working memory of mice through DRD1-PKA-CREB signaling[J]. Mol Neurobiol,2022,59(7):4292-4303. doi: 10.1007/s12035-022-02845-z
|
[5]
|
C Missale, S R Nash, S W Robinson, et al. Dopamine receptors: From structure to function[J]. Physiol Rev,1998,78(1):189-225.
|
[6]
|
Trzaskowski B,Latek D,Yuan S,et al. Action of molecular switches in GPCRs-theoretical and experimental studies[J]. Curr Med Chem,2012,19(8):1090-1109.
|
[7]
|
曹国祥. 多巴胺受体显像剂的研究概况[J]. 国外医学(放射医学核医学分册),1999,23(2):65-67
|
[8]
|
Wen X S,Chen X M,Rong F,et al. The regulation of SKF38393 on the dopamine and D1 receptor expression in hippocampus during chronic REM sleep restriction[J]. CNS Neurosci Ther,2013,19(9):730-733. doi: 10.1111/cns.12140
|
[9]
|
乔晋萍,乔洪文,武仙英,等. 多巴胺神经系统显像分子探针研究[J]. 生命的化学,2014,34(2):154-165.
|
[10]
|
Gouveri E,Katotomichelakis M,Gouveris H,et al. Olfactory dysfunction in type 2 diabetes mellitus: an additional manifestation of microvascular disease?[J]Angiology,2014,65(10): 869-876.
|
[11]
|
李瑞,范运龙,刘海鹰,等. 多巴胺D1受体在小鼠大脑皮层的空间分布研究[J]. 神经解剖学杂志,2019,35(3):229-235.
|
[12]
|
De Bundel D,Femen í a T,DuPont C M,et al. Hippocampal and prefrontal dopamine D1/5 receptor involvement in the memory-enhancing effect of reboxetine[J]. Int J Neuropsychopharmacol,2013,16(9):2041-51. doi: 10.1017/S1461145713000370
|
[13]
|
Liu A,Ding S. Anti-inflammatory Effects of Dopamine in lipopolysaccharide (LPS)-stimulated RAW264.7 cells via inhibiting NLRP3 inflammasome activation[J]. Ann Clin Lab Sci,2019,49(3):353-360.
|
[14]
|
Seamans J K,Yang C R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex[J]. Prog Neurobiol,2004,74(1):1-57. doi: 10.1016/j.pneurobio.2004.05.006
|
[15]
|
张国炳, 陈峻严, 孙文栋,等. 多巴胺D1受体基因(-48A/G)多态性与额叶挫裂伤后认知障碍相关性[J]. 中华实验外科杂志,2016,33(4):993-996.
|
[16]
|
J M Beaulieu,S Espinoza,R R Gainetdinov. Dopamine receptors - IUPHAR review 13[J]. Britisch Journal of Pharmacology,2015,172(1): 1-23.
|
[17]
|
王功伍,蔡景霞. 海马-前额叶神经回路与工作记忆[J]. 动物学研究,2010,31(1):50-56.
|
[18]
|
Tsang J,Fullard J F,Giakoumaki S G,et al. The relationship between dopamine receptor D1 and cognitive performance[J]. NPJ Schizophr,2015,4(1):14002.
|
[19]
|
El-Ghundi M,Fletcher P J,Drago J,et al. Spatiallearning deficit in dopamine D(1) receptor knockout mice[J]. Eur J Pharmacol,1999,383(2):95-106. doi: 10.1016/S0014-2999(99)00573-7
|
[20]
|
Tractenberg S G,Orso R,Creutzberg K C,et al. Vulnerable and resilient cognitive performance related to early life stress: The potential mediating role of dopaminergic receptors in the medial prefrontal cortex of adult mice[J]. Int J Dev Neurosci,2020,80(1):13-27. doi: 10.1002/jdn.10004
|
[21]
|
胡一文,王高华,顾剑. 精神分裂症患者多巴胺D1受体基因-48A/G多态性与认知功能的关系[J]. 中国神经精神疾病杂志,2006,32(6):523-526. doi: 10.3969/j.issn.1002-0152.2006.06.009
|
[22]
|
李凡,舒斯云,包新民. 多巴胺受体的结构和功能[J]. 中国神经科学杂志,2003,19(6):405-410.
|
[23]
|
Smith, Y Raju, D V Pare, et al. The thalamostriatal system: A highly specific network of the basal ganglia circuitry[J]. Trends Neurosci,2004,27(9):520-527.
|
[24]
|
Darmopil S, Mart í n A B, De Diego I R, et al. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation[J]. Biol Psychiatry,2009,66(6):603-613.
|
[25]
|
Reid K M,Steel D,Nair S,et al. Loss-of-function variants in DRD1 in infantile Parkinsonism-dystonia[J]. Cells,2023,12(7):1046.
|
[26]
|
Toma C,Herv á s A,Balmaña N,et al. Neurotransmitter systems and neurotrophic factors in autism: Association study of 37 genes suggests involvement of DDC[J]. World J Biol Psychiatry,2013,14(7):516-527. doi: 10.3109/15622975.2011.602719
|
[27]
|
Cartier E,Hamilton P J,Belovich A N,et al. Rare autism-associated variants implicate syntaxin 1 (STX1 R26Q) phosphorylation and the dopamine transporter (hDAT R51W) in dopamine neurotransmission and behaviors[J]. EBio Medicine,2015,2(2):135-146. doi: 10.1016/j.ebiom.2015.01.007
|
[28]
|
Corrales E,Navarro A,Cuenca P,et al. Candidate gene study reveals DRD1 and DRD2 as putative interacting risk factors for youth depression[J]. Psychiatry Res,2016,244(11):71-77.
|
[29]
|
Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia[J]. Life Science,1999,65(22):2269-2287.
|
[30]
|
Odum A L. Delay discounting: I'm a k,you're a k[J]. J Exp Anal Behav,2011,96(3):427-439. doi: 10.1901/jeab.2011.96-423
|
[31]
|
Bickel W K,Jarmolowicz D P,Mueller E T,et al. Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other disease-related vulnerabilities: Emerging evidence[J]. Pharmacol Ther,2012,134(3):287-297. doi: 10.1016/j.pharmthera.2012.02.004
|
[32]
|
Moses T E H,Burmeister M,Greenwald M K. Heroin delay discounting and impulsivity: Modulation by DRD1 genetic variation[J]. Addict Biol,2020,25(3):e12777. doi: 10.1111/adb.12777
|
[33]
|
Ashe M L,Newman M G,Wilson S J. Delay discounting and the use of mindful attention versus distraction in the treatment of drug addiction: A conceptual review[J]. J Exp Anal Behav,2015,103(1):234-248. doi: 10.1002/jeab.122
|
[34]
|
Lee W,Ray R,Bergen A W,et al,Thomas P. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers[J]. Pharmacogenet Genomics,2012,22(7):551-4. doi: 10.1097/FPC.0b013e3283539062
|
[35]
|
Yan. Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome[J]. Cell,2015,160(1-2):62-73. doi: 10.1016/j.cell.2014.11.047
|
[36]
|
Cosentino M,Fietta A M,Ferrari M,et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholaminessubserving an autocrine/paracrine inhibitory functional loop[J]. Blood,2007,109(2):632-642. doi: 10.1182/blood-2006-01-028423
|
[37]
|
Ferrari M,Cosentino M,Marino F,et al. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNAexpression and catecholamine production in human lymphocytes[J]. Biochem Pharmacol,2004,67(5):865-873. doi: 10.1016/j.bcp.2003.10.004
|
[38]
|
Tsunoda M. Role of catecholamine metabolism in blood pressure regulation using chemiluminescence reactiondetection[J]. Yakugaku Zasshi,2008,128(11):1589-1594 . doi: 10.1248/yakushi.128.1589
|
[39]
|
M ravec B. Role of catecholamine-induced activation of vagal afferent pathways in regulation of sympathoadrenal system activity: Negative feedback loop of stress response[J]. Endocr Regul,2011,45(1):37-41 .
|
[40]
|
Nakano K,Higashi T,Takagi R,et al,Matsushita S. Dopaminereleased by dendritic cells polarizes Th2 differentiation[J]. Int Immunol,2009,21(6):645-654. doi: 10.1093/intimm/dxp033
|
[41]
|
Zanassi P,Paolillo M,Montecucco A,et al. Pharmacological and molecular evidence for dopamine D(1) receptor expression bystriatal astrocytes in culture[J]. J Neurosci Res,1999,58(4):544-552. doi: 10.1002/(SICI)1097-4547(19991115)58:4<544::AID-JNR7>3.0.CO;2-9
|
[42]
|
Zhang X,Zhou Z,Wang D,et al. Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2expression in astrocytes via IP3-dependent Ca2+ signaling[J]. J Neurosci,2009,29(24):7766-7775 . doi: 10.1523/JNEUROSCI.0389-09.2009
|
[43]
|
Beaulieu J M,Gainetdinov R R. The physiology,signaling,and pharmacology of dopamine receptors[J]. Pharmacological Reviews,2011,63(1):182-217. doi: 10.1124/pr.110.002642
|
[44]
|
Ng J, Barral S, Waddington S N, et al. Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the clinical phenotype and precision medicine approaches[J]. Cells, 2023, 12(13):1737.Ng J, Barral S, Waddington S N, et al. Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the clinical phenotype and precision medicine approaches[J]. Cells, 2023,12(13):1737.
|
[45]
|
张超洁,商亚珍. CREB与阿尔茨海默病[J]. 承德医学院学报,2023,40(3):237-241.
|
[46]
|
Brami-Cherrier K,Valjent E,Garcia M,et al. Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: A new route to cAMP response element-binding protein phosphorylation[J]. J Neurosci,2002,22(20):8911-8921. doi: 10.1523/JNEUROSCI.22-20-08911.2002
|
[47]
|
Monsma F J,Jr.,Mahan L C,et al. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation[J]. Proc Natl Acad Sci USA,1990,87(17):6723-6727. doi: 10.1073/pnas.87.17.6723
|
[48]
|
Cosentino M,Kustrimovic N,Ferrari M,et al. cAMP levels in lymphocytes and CD4+ regulatory T-cell functions are affected by dopamine receptor gene polymorphisms[J]. Immunology,2018,153(3):337-341. doi: 10.1111/imm.12843
|
[49]
|
D’ SaC ,Duman R S . Antidepressants and neuroplasticity[J]. Bipolar Disord,2002,4(3): 183-194.
|
[50]
|
李云峰,杨明,赵毅民,等. 巴戟天寡糖对皮质酮损伤的PC12细胞的保护作用[J]. 中国中药杂志,2000,25(9):39-42.
|
[51]
|
李云峰,罗质璞. 丁螺环酮对皮质酮所致PC12细胞损伤的保护作用[J]. 中国药理学与毒理学杂志,2001,15(5):333-336.
|
[52]
|
Possemato E, La Barbera L, Nobili A, et al. The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases[J]. Ageing Res Rev,2023,87(1):101907.
|
[53]
|
Yang C,Kazanietz M G. Divergence and complexities in DAG signaling: Looking beyond PKC[J]. Trends Pharmacol Sci,2003,24(11):602-608. doi: 10.1016/j.tips.2003.09.003
|
[54]
|
Felder C C,Jose P A,Axelrod J. The dopamine-1 agonist,SKF 82526,stimulates phospholipase-C activity independent of adenylate cyclase[J]. J Pharmacol Exp Ther,1989,248(1):171-175.
|
[55]
|
Berridge M J. Inositol trisphosphate and calcium signalling mechanisms[J]. Biochim Biophys Acta,2009,1793(6):933-940. doi: 10.1016/j.bbamcr.2008.10.005
|
[56]
|
Qin D,Liu P,Chen H,et al. Salicylate-induced ototoxicity of spiral ganglion neurons: Ca2+/CaMKII-mediated interaction between NMDA receptor and GABAA receptor[J]. Neurotox Res,2019,35(4):838-847. doi: 10.1007/s12640-019-0006-8
|
[57]
|
Zeng C,Villar V A,Yu P,et al. Reactive oxygen species and dopamine receptor function in essential hypertension[J]. Clin Exp Hypertens,2009,31(2):156-178. doi: 10.1080/10641960802621283
|
[58]
|
Kansra V,Chen C J,Lokhandwala M F. Dopamine fails to stimulate protein kinase C activity in renal proximal tubules of spontaneously hypertensive rats[J]. Clin Exp Hypertens,1995,17(5):837-845. doi: 10.3109/10641969509033638
|
[59]
|
Kim B,Yun J,Park B. Methamphetamine-induced neuronal damage: Neurotoxicity and neuroinflammation[J]. Biomol Ther,2020,28(5):381-388.
|
[60]
|
Premoli M, Aria F, Bonini S A, et al. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment[J]. Life Sci,2019,224(1):120-127.
|
[61]
|
Vitale R M, Iannotti F A, Amodeo P. The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: Molecular mechanisms and targets[J]. International Journal of Molecular Sciences,2021,22(9):4876.
|